lncRNA LINC01296与非小细胞肺癌患者临床预后的关系研究

Study on relationship between lncRNA LINC01296 and prognosis in patients with non-small cell lung cancer

目的分析lncRNA LINC01296与非小细胞肺癌患者临床病理特征及其预后的关系。方法收集325例非小细胞肺癌患者的临床资料,应用RT-PCR法检测肺癌标本lncRNA LINC01296表达。采用Kaplan-Meier和Cox回归法分析肺癌患者预后的影响因素。结果LINC01296表达与性别(P=0.002)、TNM分期(P=0.001)和复发(P<0.001)相关。具有较高的LINC01296表达的患者表现出更高级别的临床特征和较短的无进展存活时间(P=0.002)和整体生存率(P<0.001)。多因素分析表明,LINC01296表达与NSCLC患者的无进展生存(HR=1.95,95%CI:1.32~2.79,P=0.008)和总生存(HR=2.25,95%CI:1.83~3.72,P=0.012)相关。结论LINC01296与NSCLC患者的无进展生存和总生存独立相关,可能是其预后的潜在生物标志物。

Objective To explore the association between lncRNA LINC01296 and clinical features and prognosis in patients with non-small cell lung cancer (NSCLC).Methods The clinical data were collected in 325 patients with NSCLC.RT-PCR was used to detect lncRNA LINC01296 expression in lung cancer tissue specimens.Kaplan-Meier and cox regression analysis were performed to investigate the influencing factors of prognosis in patients with NSCLC.Results LINC01296 expression was positively correlated with gender ( P =0.002),TNM stage ( P =0.001),and recurrence ( P =0.000).Patients with high LINC01296 expression showed advanced clinical features and shorter progression-free survival time ( P =0.002) and overall survival ( P =0.000) than those with low LINC01296 expression.Multivariate analysis showed that LINC01296 expression was an independent predictor of progression-free survival ( HR=1.95,95%CI:1.32~2.79,P =0.008) and overall survival ( HR=2.25,95%CI:1.83~3.72,P =0.012) in NSCLC patients.Conclusion The present results demonstrate that LINC01296 is associated with progression-free survival and overall survival,and it maybe a potential biomarker of prognosis.